The autonomic symptom profile - A new instrument to assess autonomic symptoms
The autonomic symptom profile - A new instrument to assess autonomic symptoms
复制标题
DOI：
10.1212/wnl.52.3.523
复制
发表时间：
1999-02-01
期刊：
影响因子：
9.9
通讯作者：
Low, PA
中科院分区：
文献类型：
--
作者：
Suarez, GA;Opfer-Gehrking, TL;Low, PA
目的：研制一种新的专用仪器——自主神经症状谱仪来测量自主神经症状并检验其有效性。背景：测量症状在评估生活质量结果中很重要。目前还没有有效的、自我完成的关于自主神经障碍患者症状的问卷。方法：问卷共169项，涉及自主神经症状的不同方面。建立项目加权复合自主症状量表（COMPASS）；分数越高表明症状越严重。进行自主功能测试以生成复合自主评分量表（CASS）并量化自主功能缺陷。我们将COMPASS的结果与来自自主反射屏幕的CASS结果进行比较，以评估有效性。结果：41名健康对照者（平均年龄46.6岁）、33名非自主周围神经病变患者（平均年龄59.5岁）和39名自主神经衰竭患者（平均年龄61.1岁）对该仪器进行了测试。COMPASS分数与CASS有良好的相关性，显示出可接受的内容水平和标准效度。对照组COMPASS总分的平均值（+/- SD）为9.8(+/- 9)，非自主周围神经病变患者为25.9(+/- 17.9)，自主神经衰竭组为52.3（+/- 24.2）。通过多元逐步回归分析，直立性不耐受和分泌运动功能障碍的评分最能预测CASS。结论：我们描述了一份测量自主神经症状的问卷，并为其有效性提供了证据。该仪器在临床试验和流行病学研究中显示出评估自主神经症状的前景。
Objective: To develop a new specific instrument called the Autonomic Symptom Profile to measure autonomic symptoms and test its validity. Background: Measuring symptoms is important in the evaluation of quality of life outcomes. There is no validated, self-completed questionnaire on the symptoms of patients with autonomic disorders. Methods: The questionnaire is 169 items concerning different aspects of autonomic symptoms. The Composite Autonomic Symptom Scale (COMPASS) with item-weighting was established; higher scores indicate more or worse symptoms. Autonomic function tests were performed to generate the Composite Autonomic Scoring Scale (CASS) and to quantify autonomic deficits. We compared the results of the COMPASS with the CASS derived from the Autonomic Reflex Screen to evaluate validity. Results: The instrument was tested in 41 healthy controls (mean age 46.6 years), 33 patients with nonautonomic peripheral neuropathies (mean age 59.5 years), and 39 patients with autonomic failure (mean age 61.1 years). COMPASS scores correlated well with the CASS, demonstrating an acceptable level of content and criterion validity. The mean (+/- SD) overall COMPASS score was 9.8 (+/- 9) in controls, 25.9 (+/- 17.9) in the patients with nonautonomic peripheral neuropathies, and 52.3 (+/- 24.2) in the autonomic failure group. Scores of symptoms of orthostatic intolerance and secretomotor dysfunction best predicted the CASS on multiple stepwise regression analysis. Conclusions: We describe a questionnaire that measures autonomic symptoms and present evidence for its validity. The instrument shows promise in assessing autonomic symptoms in clinical trials and epidemiologic studies.